ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1116

Anti-Citrullinated Protein Antibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway

Meng Sun1, Vijay Joshua1, Akilan Krishnamurthy1, Yanying Liu2, Aase Hensvold1, Sergiu-Bogdan Catrina3, Caroline Ospelt4, Vivianne Malmström5, Khaled Amara1, Johanna Steen1, Muhammad Sohel Mia1, Marianne Engström1, Heidi Wähämaa1, Jimmy Ytterberg1, Bence Rethi1 and Anca I Catrina1, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Peking University People's Hospital, Beijing, China, 3Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4University Hospital Zurich, Center of Experimental Rheumatology, Switzerland, Zurich, Switzerland, 5Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ACPA, fibroblasts and synovial cells, PAD, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Synovial fibroblasts (SFs) contribute to rheumatoid arthritis (RA) pathogenesis by growing into the synovial space and by producing pro-angiogenic and tissue remodelling factors, chemokines and inflammatory cytokines that recruit and stimulate various immune cells. We have recently demonstrated that anti-citrullinated proteins antibodies (ACPAs) promote osteoclastogenesis through an interleukin-8 (IL-8) dependent autocrine mechanism. In the present work we investigated alterations of synovial fibroblast morphology and behaviour in response to ACPAs, including signalling transduction, cytokine production and mobility.

Methods: SFs were isolated from synovial tissue of RA patients by enzymatic digestion. Polyclonal ACPA and others non-ACPA IgGs were separated from peripheral blood of RA patients by affinity purification on cyclic citrullinated peptide (CCP)-2 column. SF migration capacity were tested by scratch-assays in presence of various stimuli, including ACPAs, non-ACPA IgGs, TNF and IL-8 using starved cells. The results were evaluated by NIH ImageJ software. SF adhesion was analyzed by xCELLigence System Real-Time Cell Analyzer (ACEA bioscience). Cytokine production was detected in supernatant by cytometric bead array. Signaling cascades were targeted using inhibitors of phosphoinositide 3-kinase (PI3K), phosphatase and tensin homolog (PTEN), G-protein coupled receptors (GPCRs), focal adhesion kinase (FAK) and peptidylarginine deiminases (PAD) in scratching assays. Protein phosphorylations were monitored by western blot.

Results: Polyclonal ACPAs but not non-ACPA IgGs induced migration (a fold increase of 2.6±0.5, mean±SD, p<0,05) and adhesion (a fold increase of 1.3±0.1 at 6 hours, p<0.05) after starvation. The cytokines TNF and IL-8 synergistically increased SF migration in presence of ACPAs. By inhibiting PADs, the enzymes responsible for protein citrullination, we showed that PAD activity is needed for the ACPA effects but not for baseline SF mobility. GPCR and PI3K blocking inhibited the effects of ACPAs whereas PTEN blocking enhanced migration, indicating important roles for GPCR and PI3K in the ACPA-mediated SF modulation. Immunoblot analysis revealed an increased AKT phosphorylation in ACPA-treated cells, further suggesting the involvement of PI3K in the ACPA-mediated signals.

Conclusion: ACPAs promote SFs migration and adhesion acting synergistically with IL-8 through a PAD-dependent pathway. Our findings suggest that SFs might have an active role in the ACPA-dependent disease propagation from the bone marrow to synovial tissue during RA.


Disclosure: M. Sun, None; V. Joshua, None; A. Krishnamurthy, None; Y. Liu, None; A. Hensvold, None; S. B. Catrina, None; C. Ospelt, None; V. Malmström, None; K. Amara, None; J. Steen, None; M. S. Mia, None; M. Engström, None; H. Wähämaa, None; J. Ytterberg, None; B. Rethi, None; A. I. Catrina, None.

To cite this abstract in AMA style:

Sun M, Joshua V, Krishnamurthy A, Liu Y, Hensvold A, Catrina SB, Ospelt C, Malmström V, Amara K, Steen J, Mia MS, Engström M, Wähämaa H, Ytterberg J, Rethi B, Catrina AI. Anti-Citrullinated Protein Antibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/anti-citrullinated-protein-antibodies-promote-synovial-fibroblasts-migration-and-adhesion-through-a-peptidylarginine-deiminases-pad-dependent-pathway/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-protein-antibodies-promote-synovial-fibroblasts-migration-and-adhesion-through-a-peptidylarginine-deiminases-pad-dependent-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology